Youmanitarian
Youmanitarian 12 Jun 2021

Up next

Understand Cancer & Reduce Cancer Risk | Dr. Peter Attia & Dr. Andrew Huberman
24 May 2023
Understand Cancer & Reduce Cancer Risk | Dr. Peter Attia & Dr. Andrew Huberman
uchetex · 12 Views

Advances in recurrent endometrial cancer: adavosertib, a WEE1 inhibitor

14 Views
TAKE ACTION
Donations would go to support charities for #HEALTHCARE / Uterine Cancer

Ursula Matulonis, MD, Dana-Farber Cancer Institute, Boston, MA evaluates advances in recurrent endometrial cancer treatment and highlights the development of adavosertib, a WEE1 inhibitor that shows over a 30% response rate and represents an additional therapy for patients with recurrent endometrial cancer. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Show more
More ways to take action
Explore ways that you can help bring a solution to this issue.

Up next

Understand Cancer & Reduce Cancer Risk | Dr. Peter Attia & Dr. Andrew Huberman
24 May 2023
Understand Cancer & Reduce Cancer Risk | Dr. Peter Attia & Dr. Andrew Huberman
uchetex · 12 Views